Immune-mediated hepatitis. A literature review
Open Access
- 12 October 2026
- journal article
- Published by Association of Oncologist Real Clinical Practice OncoPractitioner in Clinical Case in Oncology
- Vol. 4 (1) , 21-39
Abstract
Aim. Immune checkpoint inhibitors (ICIs) have transformed the standards of systemic therapy across a broad range of malignancies; however, the expansion of their indications has inevitably been accompanied by a rise in immunerelated adverse events. The aim of this review is to summarise current understanding of the pathogenesis, clinical presentation, incidence, differential diagnosis and management of immune-mediated hepatitis associated with immune checkpoint inhibitor therapy, comparing the approaches adopted by international and Russian professional societies.Methods. Publications were searched in PubMed/MEDLINE and eLIBRARY, as well as on the official websites of the professional societies ASCO (American Society of Clinical Oncology), ESMO (European Society for Medical Oncology), RUSSCO (Russian Society of Clinical Oncology) and NCCN (National Comprehensive Cancer Network), and of regulatory agencies (FDA Food and Drug Administration). Current clinical guidelines, official prescribing information, systematic reviews, meta-analyses, randomised trials and real-world data were included. Results. The liver ranks third among the organs affected, after the skin and the gastrointestinal tract. According to the integrated safety databases of regulatory agencies, the incidence of immune-mediated hepatitis was 0.7% for pembrolizumab, 1.8% for nivolumab and atezolizumab, 2.8% for durvalumab, and 7.0 to 15.0% for nivolumab combined with ipilimumab, depending on the dose ratio. PD-1 inhibitors were associated with more frequent transaminase elevations than PD-L1 inhibitors. Management is based on stepwise immunosuppression; mycophenolate mofetil is the second-line agent, whereas infliximab is not used in hepatic involvement.Conclusion. Immune-mediated hepatitis requires differential diagnosis, since a substantial proportion of liver test elevations is due to alternative causes. The extent of immunosuppression should be matched to the clinical severity of the condition rather than to the formal CTCAE grade alone.Keywords
This publication has 39 references indexed in Scilit:
- Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristicsHepatology International, 2024
- AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injuryHepatology, 2023
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter StudyClinical Gastroenterology and Hepatology, 2022
- Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitisHepatology, 2021
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With SorafenibJAMA Oncology, 2020
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With CancerJAMA Oncology, 2020
- Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management RecommendationHepatology, 2020
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroidsJournal of Hepatology, 2017